eli lilly sold $5 billion worth of sim balance at a making it one of the all time best sellers. sales fell after the u.s. patent expired opening the door for generics. but demand for other products grew and earnings came in as expected. in march, lilly loses another patent on avista that treats bone disease. the ceo is confident about bringing new cancer and diabetes drugs to market. >> we've been investing in our pipe line and have four medic e medicines under regulatory review and could launch as many as three this year. this is the inflection year and we hope the launches will put us back on a growth track. >> under armour and pulte homes and northrop grumman rose with under armour up 23%. 3m fell as did colgate and eli lilly. >>> we begin the market focus with strong earnings out of viacom, cost cutting made up for a big decline in movie revenue. it expects to add revenue to improve this quarter and that sent shares up to $84.01. time warner cable saw a rise. the revenue from its business services and residential high speed data kept those results afloat despite a drop in ov

in this quarter, john lechleiter, ceo of eli lilly. this quarter was cymbalta. ff, john. >> that went off patent in early december. this has obviously been one of lilly's most successful products. when you lose a patent in the united states you see a rapid decline of revenue. that brought sales for the quarter down 2%. looking beyond that if you take cymbalta, in the united states off, our revenue growth was 9%. we feel good about that. that was a contribution from a range of other products. >> what is cymbalta? >> cymbalta is called an snri, created for the treatment of depression and other conditions. >> it used to be re-up take. what's the n? >> nurepinephrine. >> osteo, that goes off two months from now. >> we lose the avista patent in march of this year, in about six weeks. we saw these things coming. we've been planning for this. we've been investing in our pipeline. we have four medicines under regulatory review currently. we could launch as many as three of those this year. this is really the inflection year for us. we hope those launches will put us back

eli lilly stock is featured. it went nowhere in 2013 but how about 2014?pany's ceo opens up his medicine cabinet exclusively for us from that big meeting. >>> and the health care sector a leader in 2014 so far. dominic chu is looking at the best performers. >> they were leaders in 2013 as well, the second best performing sector in the entire s&p. but health care has a whole different concept of components, insurers, drug companies. we will go through those and their performance next on "power lunch." start the engine... and shift through all eight speeds of a transmission connected to more standard horsepower than its german competitors. and that is the moment that driving the lexus gs will shift your perception. this is the pursuit of perfection. i worked a patrol unit for 17 years in the city of baltimore. when i first started experiencing the pain, it's, it's hard to describe because you have a numbness... but yet you have the pain like thousands of needles sticking in your foot. it was progressively getting worse, and at that point i knew i had to do s

fake studies to put millions of lives at risk do we have documented precedents this is exactly like eli lilly which in the one nine hundred eighty s. knew that prozac was leading to suicides and aggressive behavior the exact opposite effect of what they wanted they knew that in the one nine hundred eighty s. after they conducted the research they hid the research and it wasn't exposed and told two thousand and five from the b.b.c. but then they would have their corporate interests do studies and talk about how great it was now of course they're required to admit yeah that antidepressants do cause suicide aggressive behavior pretty much every shooters on them when these cell phone companies are forced to admit yeah the cell phone radiation does cause brain to. you know it does do all this and they're already saying this in their manuals so it's already coming out but once the public is aware of this fact it will be even worse oppresses it will be even worse than tobacco we invited the powerful industry lobby c.t. i used to discuss the issues raised in this report they sent this one line refusa

auto nation and eli lilly. plus we have investing legend and a contend either for the first 25.ight now, let's get to the global markets, though. after yesterday's rough right on wall street, stocks in asia fell overnight. the nikkei closing down nearly 2.5%. that was significantly off the lows of the session. and if you look at what happens on wednesday, the stocks there were up by 2.7%. so this is really just a give back. but among the reasons that were listed for this sell-off, you have data showing signs of a contraction in china's economy and the fed's decision to continue with the taper. in europe european trading this morning, you can see there are red heir rows across the board. italy off by more than 0.5%.

general mills, kellogg, eli lilly, pfizer, coca-cola, j&j.t was almost as if these stocks caught the plague. if you stayed with them or didn't pay back your positions because you wanted to be diversified, i don't blame you one bit. your portfolio simply stopped increasing in value. it's important to recognize that unless there was a new breakthrough drug or fda approval, as was the case with gilead, and the hepatitis c drug, the same underlying performance hit in bio tech, stopping this once red-hot group in its tracks. now, let's compare that with a couple of industrials. take 3-m. despite some vicious downgrades, including a sale from one important firm, this stock would not quit. buy buy buy. when it was hammered by the downgrade, lots of people wrote off 3-m. but the more excellent growth numbers are showing it, it kept soaring, or consider union pacific. they preannounced the short fall and then it had a sustained advance. it wasn't just the trains though. despite endless and may i saw worthless valuation downgrades of federal express, t

i can understand how a growth company like merck or ely lilly might make a tender offer. back when they had no earnings or sales to speak of. these growth challenge dinosaurs could do worse than paying $11 billion for the $8 billion company if the drug turns out as miraculous as it sounds. gilead's stock went up. these stocks, i'm telling you, if their ceos picked up a phone and bought intercept this weekend, their stocks would go up, too. not down, but up. lots of people think the official kickoff for earnings season is not alcoa. it's reported yesterday. but actually with the banks. i think it really does start when jpmorgan and wells fargo start talking next tuesday. these two banks pretty much define the financial universe with jpm being the quintessential investment house. and in truth, they all do a little bit of everything. but they do one thing really well. they make a ton of money! which is why i like them so much. that will be obscured in the case of jpmorgan and charitable trust name by the myriad of lawsuits it's invested in. memo to jamie dimon ceo, settle mo

i can understand how a growth strapped company mick merck or ely lilly might make a tender offer for intercept. just like pharma cpt. back when they had no earnings or sales to speak of. these growth challenge dinosaurs could do worse than paying $11 billion for the $8 billion company if the drug turns out as miraculous as it sounds. gilead's stock went up. these stocks, i'm telling you, lille and merck, if their ceos picked up a phone and bought intercept this weekend, their stocks would go up, too. not down, but up. lots of people think the official kickoff for earnings season is not alcoa. it's reported yesterday. but actually with the banks. i think it really does start when jpmorgan and wells fargo start talking next tuesday. these two banks pretty much define the financial universe with jpm being the quintessential investment house. wells fargo is a mortgage machine. and in truth, they all do a little bit of everything. but they do one thing really well. they make a ton of money! which is why i like them so much. that will be obscured in the case of jpmorgan and charitable trus

. >> eli lilly. >> goldman sachs. >> eastman chemical. >> see you tomorrow.busy 59:30 of "power lunch." on the agenda, the top fund managers of the year. who should you follow in 2014? "power lunch" is live with morningstar's list. plus apple goes to china, gm gets a new ceo and a dividend. jersey's big gamble online, is it paying off? gold, oil, a new way to buy a car and silicon valley. this is one powerful hour of "power lunch" leading you into the key number of the day. facebook at 2:00 eastern could

a lot of value creating things like merck and eli lilly are embracing today, pfizer embraced several years ago. they were a trendsetter. to give credit where credit is due, bristol-myers did this five years ago. they're later in the recovery game, if you will. so now for pfizer to out perform its peers, stuff has to go right. why mean by stuff is they need to develop new drugs for important diseases and they are the lead drug i focus on at pfizer is for breast cancer. we'll see data on that no later than late may or earl my june this year. if that data is positive i would expect pfizer to show signs of life again. >> always grate insights, thanks for coming on. >> thanks for having me. >> he is a rarity. a real from and plays one on tv. >> i play one on tv and i like a lot of the sort of pharma names i'm looking at are the ones in there on the obesity side, judge. vivus, arena pharmaceutical. all of these, i'm focus and those right now. the alumina partnership is key for them on the oncology drug there. >>> could yahoo! investors soon be hearing this sound? >> you got mail. >> well,

>> eli lilly. i own the stock. i bought calls. >> anthony, the birthday boy, your final trade?the cupcakes. >> there's like 300 cupcakes over there. it will be a parade from the newsroom. >> doc? >> cx. lot of call buying. >> dow down 43 points. "power lunch" picks up the ball. see you tomorrow. >>> "power lunch" and the second half of the trading day start right now. >> happy birthday, anthony. be grateful you're not flying, at least not this afternoon. what a mess. if you are a business traveler, and you're in the airways this week, you are probably going to face delays. the airlines are sorting out schedules after a very, very tough week and now more weather problems on the way. record low temperatures hitting the midwest, dipping down into the south and moving east. big time. >>> the government closes in on a deal. there's the man, there's the bank involved. jpmorgan's relationship with

. >> eli lilly. >> goldman sachs. >> eastman chemical. >> see you tomorrow. "power lunch" starts right now. >>> it's a busy 59:30 of "power lunch." on the agenda, the top fund managers of the year. who should you follow in 2014? "power lunch" is live with morningstar's list. plus apple goes to china, gm gets a new ceo and a dividend. jersey's big gamble online, is it paying off? gold, oil, a new way to buy a car and silicon valley. this is one powerful hour of "power lunch" leading you into the key number of the day. facebook at 2:00 eastern could be a market mover. here's sara eisen at cnbc global headquarters and tyler matheson in chicago. >> good afternoon. the markets are up big. the dow gaining 230 points in just two days. >> i'm here in chicago as was just said, at the morningstar annual fund manager of the year award. it is perhaps the biggest event in the entire mutual fund industry. think of it as kind of the golden globes minus the alcohol. i will be somewhere between tina fey and if you watched sunday night, jacqueline bissett. rea we are joined by

. >> eli lilly, the drugmaker reporting fourth-quarter profit slightly below analyst estimates but waslling revenues in some of the generic drugs and competition for the malta -- zymbalta. citrix systems, fourth-quarter earnings beat analysts estimates but issued a disappointing full-year forecast. it also announced that ceo is going to be retiring within the next well month. at least two analysts have downgraded the stock this morning. >> pandora. shares surging in the premarket. goldman sachs saying the stock could hit 60 bucks at the company doubles the ad load. i recently found pandora and now i love it. >> way behind. number five, las vegas sands, the world largest casino company reporting fourth-quarter earnings that trailed analyst estimates and sales in singapore fell. they did reported double-digit jump, though, a revenue and las vegas operations. number four, time warner cable, fending off a $37 billion buyout did by charter communications, the fourth quarter estimates, higher fees made up for it. another 200 that -- higher fees made up for another 200,000 subscribers leading

once employment started getting better, the eli lillys of the world were stopped in their tracks.ay that you saw an alcoa, norfolk southern, union pacific, union pacific preannounces and finishes at 116. a coal company goes to 77 and then rallies. fedex preannounced and you called it the teflon stock. and speaking of teflon, dupont, 64. industrials. >> that's where we need to be focused in the first quarter certainly, the industrials. overall the market is still, many would say, it's 14.5, 15 times numbers. we're still in a low interest rate, low-inflation environment and you could argue for a higher multiple. those are arguing we might get to 16, 17, 18 times and still be okay with it. >> if we get to that. i've done a lot of calculation in preparation for tonight's "mad money." that would produce a 15% to 17% increase in the dow if we got that multiple expansion. but one of the things that happened at the end of the year that shocked me, you begin to get an exxon, almost like a small cap run, it's incredible to see that. don't forget the whole complex of mobile and social and ye